Incyte is a global biopharmaceutical company focused on the discovery, development, and commercialization of proprietary therapeutics. The company's core business model centers around its hematology/oncology and inflammation/autoimmunity franchises. Incyte's primary revenue streams are derived from sales of its approved products, including JAKAFI, OPZELURA, ICLUSIG, PEMAZYRE, MINJUVI and ZYNYZ. The company has a global presence with operations in the United States, Europe, Japan and Canada. Incyte faces competition from other pharmaceutical and biotechnology companies, as well as academic and research institutions.

• Employees: 2,524 (as of December 31, 2023)
• Geographic Footprint: United States, Canada, Europe, and Japan
• Headquarters: Wilmington, Delaware
• Founded: 1991
• Number of locations/facilities: Multiple offices across the US, Europe, Japan and Canada, with a large molecule production facility in Yverdon, Switzerland
• Revenue: $3.7 billion (FY2023)
• Market Capitalization: Approximately $11.7 billion (as of June 30, 2023)
• Key Subsidiaries/Brands: JAKAFI, OPZELURA, ICLUSIG, PEMAZYRE, MINJUVI, ZYNYZ

• CEO: Hervé Hoppenot
• CFO: Christiana Stamoulis
• Other Key Executives:
  • Pablo J. Cagnoni, President and Head of Research and Development
  • Sheila Denton, Executive Vice President, General Counsel and Corporate Secretary
  • Jonathan E. Dickinson, Executive Vice President and General Manager, Europe
  • Barry P. Flannelly, Executive Vice President and General Manager, North America
  • Vijay Iyengar, Executive Vice President, Global Strategy and Corporate Development
  • Michael Morrissey, Executive Vice President and Head of Global Technical Operations
  • Steven Stein, Executive Vice President and Chief Medical Officer
  • Paula J. Swain, Executive Vice President, Human Resources

Key leaders have extensive experience in the pharmaceutical and biotechnology industries.

• Annual Revenue: $3.7 billion (FY2023)
• Net Income: $597.6 million (FY2023)
• Market Cap: Approximately $11.7 billion (as of June 30, 2023)
• Total Assets: $6.8 billion (as of December 31, 2023)
• Employees: 2,524 (as of December 31, 2023)
• Key Financial Highlights: Net income increased to $597.6 million in 2023 from $340.7 million in 2022. Product revenues increased to $3.2 billion in 2023 from $2.7 billion in 2022.

Incyte's main product categories include:

• Hematology/Oncology:
  • JAKAFI (ruxolitinib): An oral JAK1 and JAK2 inhibitor approved for myelofibrosis, polycythemia vera, and graft-versus-host disease.
  • ICLUSIG (ponatinib): A kinase inhibitor for chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
  • PEMAZYRE (pemigatinib): A selective FGFR kinase inhibitor for cholangiocarcinoma and myeloid/lymphoid neoplasms.
  • MONJUVI/MINJUVI (tafasitamab): An anti-CD19 antibody for diffuse large B-cell lymphoma.
  • ZYNYZ (retifanlimab-dlwr): A humanized monoclonal antibody targeting programmed death receptor-1 (PD-1) for Merkel cell carcinoma.
• Inflammation and Autoimmunity:
  • OPZELURA (ruxolitinib) cream: A topical JAK1 and JAK2 inhibitor for atopic dermatitis and nonsegmental vitiligo.

Incyte operates in two main therapeutic areas:

• Hematology/Oncology: Includes treatments for myeloproliferative neoplasms, graft-versus-host disease, solid tumors, and hematologic malignancies.
• Inflammation and Autoimmunity: Includes treatments for atopic dermatitis and vitiligo.

The company does not provide a revenue breakdown by segment.

Incyte's business strategy focuses on:

• Discovering and developing novel therapeutics that address unmet medical needs.
• Expanding the commercial reach of its approved products.
• Pursuing strategic collaborations and licensing agreements to enhance its pipeline.
• Investing in research and development to advance new drug candidates.
• Managing its supply chain and quality assurance resources.

The company is also focused on expanding its operations outside of the United States and is investing in new technologies and methods of preventing or reducing the incidence of disease.

Incyte operates primarily in the biopharmaceutical industry, which is characterized by:

• Market Position: Incyte is a global biopharmaceutical company with a growing portfolio of approved products.
• Key Competitors: Incyte faces competition from other pharmaceutical and biotechnology companies, as well as academic and research institutions. Major competitors include companies with products in the hematology/oncology and dermatology spaces.
• Industry Trends: Key market trends include increasing demand for targeted therapies, advancements in drug discovery technologies, and evolving regulatory landscapes.

• Commercial Risks: Dependence on JAKAFI revenues, competition from other products, and challenges in obtaining and maintaining reimbursement.
• Development Risks: Uncertainty in drug discovery and development, potential delays or failures in clinical trials, and reliance on third-party manufacturers and collaborators.
• Regulatory Risks: Failure to comply with applicable laws and regulations, potential loss of regulatory approvals, and changes in government healthcare policies.
• Financial Risks: Dependence on third-party payors, fluctuations in foreign currency exchange rates, and the need for additional capital.
• Operational Risks: Dependence on key employees, business disruptions, and potential data security breaches.